You are here
First NorDiag contract in US
25 June 2008: NorDiag has entered an contract with ARUP in Salt Lake City, US for the purchase of a `Magnatrix 8000 Plus` instrument for automated PCR and Sequencing Cleanup, which includes the use of NorDiag unique particle technology. This is the first instrument sold in the United States by NorDiag.
`We are very pleased to have the opportunity to work with the genetic testing laboratory at ARUP. This is a premier reference laboratory for molecular diagnostics` said Nancy Murphy, President of NorDiag Inc. the US subsidiary of NorDiag ASA.
ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and an enterprise of the University of Utah and its Department of Pathology. ARUP has more than 2,000 employees, and offers over 2,000 tests, ranging from routine screening tests to highly esoteric molecular and genetic assays.
Contact: CEO Mårten Wigstøl Phone. +47 911 65775
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com